
Please try another search
Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company that specializes in the discovery and development of next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company utilizes an expanded genetic code technology platform to advance a portfolio of clinical and preclinical programs focused on optimizing efficacy and safety in multiple cancer indications. Ambrx's proprietary antibody-drug conjugats (ADC) include Arx517 for targeting the prostate-specific membrane antigen (Psma) and Arx788 for targeting HER2. It was spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of its protein engineering technology.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review